Passage Bio Inc. (PASG) NASDAQ
$1.27 0.04 (3.25%)
Market Cap: $75.78M
As of 04/16/24 02:45 PM EDT. Market open.
Passage Bio Inc. (PASG)
NASDAQ
$1.27
0.04 (3.25%)
Market Cap: $75.78M
As of 04/16/24 02:45 PM EDT. Market open.
Add to Portfolio
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã?-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to ... read more
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã?-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou read less
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
111
Address
.
PRICE CHART FOR PASSAGE BIO INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.27
Previous Close
$1.23
Days Range
$1.23 - $1.36
52 week range
$0.58 - $1.79
Volume
28,247
Avg. Volume (30 days)
529,264
Market Cap
$75.78M
Dividend Yield
-
P/E
-
Shares Outstanding
61,611,796
Open
$1.27
Previous Close
$1.23
Days Range
$1.23 - $1.36
52 week range
$0.58 - $1.79
Volume
28,247
Avg. Volume (30 days)
529,264
Market Cap
$75.78M
Dividend Yield
-
P/E
-
Shares Outstanding
61,611,796
FINANCIAL STATEMENTS FOR PASSAGE BIO INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR PASSAGE BIO INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Borthwick Kathleen | SVP, INTERIM CFO | Feb 13, 2024 | Sale | $0.97 | 1,470 | 1,426 | 28,466 | Feb 13, 2024, 07:36 PM |
| Forman Mark S | CHIEF MEDICAL OFFICER | Feb 13, 2024 | Sale | $0.97 | 1,638 | 1,589 | 48,631 | Feb 13, 2024, 07:34 PM |
| King Simona | Chief Financial Officer | Jul 28, 2023 | Sale | $0.88 | 11,453 | 10,079 | 23,994 | Aug 01, 2023, 04:36 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jun 28, 2023 | Buy | $0.84 | 575,195 | 483,164 | 8,034,000 | Jun 29, 2023, 04:42 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jun 27, 2023 | Buy | $0.84 | 617,382 | 518,601 | 7,458,805 | Jun 29, 2023, 04:42 PM |
| Fotopoulos Alexandros | Chief Technical Officer | Jun 16, 2023 | Sale | $0.93 | 4,052 | 3,778 | 28,693 | Jun 20, 2023, 04:10 PM |
| King Simona | Chief Financial Officer | Apr 18, 2023 | Sale | $1.05 | 2,053 | 2,156 | 2,053 | Apr 20, 2023, 04:28 PM |
| Kapadia Sandip | Director | Dec 01, 2022 | Sale | $1.19 | 5,000 | 5,964 | 0 | Dec 02, 2022, 05:14 PM |
| Fotopoulos Alexandros | Chief Technical Officer | Nov 22, 2022 | Sale | $1.33 | 3,720 | 4,948 | 20,245 | Nov 25, 2022, 04:15 PM |
| Toernsen Monika Maria | Chief Commercial Officer | Sep 19, 2022 | Sale | $1.51 | 1,681 | 2,539 | 3,319 | Nov 18, 2022, 05:01 PM |
| ORBIMED ADVISORS LLC | 10% Owner | May 04, 2022 | Buy | $1.94 | 303,500 | 588,790 | 6,841,423 | May 05, 2022, 05:23 PM |
| ORBIMED ADVISORS LLC | 10% Owner | May 03, 2022 | Buy | $1.93 | 221,500 | 427,495 | 6,537,923 | May 05, 2022, 05:23 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 20, 2022 | Buy | $5.00 | 50,800 | 254,000 | 6,316,423 | May 05, 2022, 05:11 PM |
| Goldsmith Bruce A | CEO and President | Mar 21, 2022 | Buy | $3.15 | 10,000 | 31,500 | 15,983 | Mar 23, 2022, 04:43 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 20, 2022 | Buy | $5.42 | 369,100 | 2,000,522 | 6,634,723 | Jan 24, 2022, 04:44 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 19, 2022 | Buy | $5.11 | 43,300 | 221,263 | 6,265,623 | Jan 20, 2022, 06:03 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 18, 2022 | Buy | $5.46 | 114,700 | 626,262 | 6,222,323 | Jan 20, 2022, 06:03 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 14, 2022 | Buy | $5.60 | 10,300 | 57,680 | 6,107,623 | Jan 20, 2022, 06:03 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 13, 2022 | Buy | $5.52 | 41,800 | 230,736 | 6,097,323 | Jan 13, 2022, 07:37 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 12, 2022 | Buy | $5.65 | 100,000 | 565,000 | 6,055,523 | Jan 13, 2022, 07:37 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Jan 11, 2022 | Buy | $5.53 | 8,200 | 45,346 | 5,955,523 | Jan 13, 2022, 07:37 PM |
| Quigley Jill M. | Chief Operating Officer | Dec 08, 2021 | Option Exercise | $0.23 | 71,975 | 16,554 | 368,754 | Dec 10, 2021, 05:30 PM |
| Romano Gary | Chief Medical Officer | Mar 15, 2021 | Option Exercise | $8.07 | 10,000 | 80,700 | 10,000 | Mar 17, 2021, 09:12 PM |
| Romano Gary | Chief Medical Officer | Mar 15, 2021 | Sale | $21.10 | 10,000 | 211,013 | 1,617 | Mar 17, 2021, 09:12 PM |
| Quigley Jill M. | Chief Operating Officer | Jan 20, 2021 | Sale | $30.01 | 1,300 | 39,011 | 295,284 | Jan 22, 2021, 05:54 PM |
| Quigley Jill M. | Chief Operating Officer | Jan 14, 2021 | Sale | $30.10 | 16,298 | 490,570 | 296,584 | Jan 15, 2021, 08:29 PM |
| Countouriotis Athena | Director | Mar 24, 2020 | Buy | $14.98 | 10,000 | 149,750 | 18,900 | Mar 25, 2020, 08:26 PM |
| Ratcliffe Liam | Director | Mar 03, 2020 | Buy | $18.00 | 550,000 | 9,900,000 | 2,616,630 | Mar 13, 2020, 05:20 PM |
| Ratcliffe Liam | Director | Mar 03, 2020 | Buy | $18.00 | 2,800 | 50,400 | 2,800 | Mar 13, 2020, 05:20 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Feb 28, 2020 | Buy | $18.00 | 373,300 | 6,719,400 | 373,300 | Mar 03, 2020, 07:07 PM |
| Versant Venture Capital VI, L.P. | 10% Owner | Mar 03, 2020 | Buy | $18.00 | 225,000 | 4,050,000 | 933,352 | Mar 03, 2020, 07:03 PM |
| Frazier Life Sciences IX, L.P. | 10% Owner | Mar 03, 2020 | Buy | $18.00 | 550,000 | 9,900,000 | 5,009,219 | Mar 03, 2020, 06:59 PM |
| Woiwode Thomas | Director | Mar 03, 2020 | Buy | $18.00 | 225,000 | 4,050,000 | 933,352 | Mar 03, 2020, 06:57 PM |
| Heron Patrick J | Director | Mar 03, 2020 | Buy | $18.00 | 550,000 | 9,900,000 | 5,009,219 | Mar 03, 2020, 06:54 PM |
| Yamada Tadataka | Director | Mar 03, 2020 | Buy | $18.00 | 6,500 | 117,000 | 656,149 | Mar 03, 2020, 06:51 PM |
| Ratcliffe Liam | Director | Mar 03, 2020 | Buy | $18.00 | 2,800 | 50,400 | 2,800 | Mar 03, 2020, 06:48 PM |
| Quigley Jill M. | Chief Operating Officer | Mar 03, 2020 | Buy | $18.00 | 1,000 | 18,000 | 1,000 | Mar 03, 2020, 06:46 PM |
| Quigley Jill M. | Chief Operating Officer | Mar 03, 2020 | Buy | $18.00 | 1,500 | 27,000 | 311,494 | Mar 03, 2020, 06:46 PM |
| Morris Richard Steven | Chief Financial Officer | Mar 03, 2020 | Buy | $18.00 | 400 | 7,200 | 400 | Mar 03, 2020, 06:44 PM |
| Kapadia Sandip | Director | Mar 03, 2020 | Buy | $18.00 | 5,000 | 90,000 | 5,000 | Mar 03, 2020, 06:43 PM |
| Islam Saqib | Director | Mar 03, 2020 | Buy | $18.00 | 5,000 | 90,000 | 5,000 | Mar 03, 2020, 06:41 PM |
| Goldsmith Bruce A | CEO and President | Mar 03, 2020 | Buy | $18.00 | 1,100 | 19,800 | 1,100 | Mar 03, 2020, 06:40 PM |
| Fotopoulos Alexandros | Chief Technical Officer | Mar 03, 2020 | Buy | $18.00 | 5,500 | 99,000 | 5,500 | Mar 03, 2020, 06:38 PM |
| Countouriotis Athena | Director | Mar 03, 2020 | Buy | $18.00 | 8,900 | 160,200 | 8,900 | Mar 03, 2020, 06:37 PM |
| Cale Edgar B. | GC and Corporate Secretary | Mar 03, 2020 | Buy | $18.00 | 2,000 | 36,000 | 2,000 | Mar 03, 2020, 06:35 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Borthwick Kathleen | SVP, INTERIM CFO | 02/13/2024 | 1,426 |
| Forman Mark S | CHIEF MEDICAL OFFICER | 02/13/2024 | 1,589 |
| King Simona | Chief Financial Officer | 07/28/2023 | 10,079 |
| ORBIMED ADVISORS LLC | 10% Owner | 06/28/2023 | 483,164 |
| ORBIMED ADVISORS LLC | 10% Owner | 06/27/2023 | 518,601 |
| Fotopoulos Alexandros | Chief Technical Officer | 06/16/2023 | 3,778 |
| King Simona | Chief Financial Officer | 04/18/2023 | 2,156 |
| Kapadia Sandip | Director | 12/01/2022 | 5,964 |
| Fotopoulos Alexandros | Chief Technical Officer | 11/22/2022 | 4,948 |
| Toernsen Monika Maria | Chief Commercial Officer | 09/19/2022 | 2,539 |
| ORBIMED ADVISORS LLC | 10% Owner | 05/04/2022 | 588,790 |
| ORBIMED ADVISORS LLC | 10% Owner | 05/03/2022 | 427,495 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/20/2022 | 254,000 |
| Goldsmith Bruce A | CEO and President | 03/21/2022 | 31,500 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/20/2022 | 2,000,522 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/19/2022 | 221,263 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/18/2022 | 626,262 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/14/2022 | 57,680 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/13/2022 | 230,736 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/12/2022 | 565,000 |
| ORBIMED ADVISORS LLC | 10% Owner | 01/11/2022 | 45,346 |
| Quigley Jill M. | Chief Operating Officer | 12/08/2021 | 16,554 |
| Romano Gary | Chief Medical Officer | 03/15/2021 | 80,700 |
| Romano Gary | Chief Medical Officer | 03/15/2021 | 211,013 |
| Quigley Jill M. | Chief Operating Officer | 01/20/2021 | 39,011 |
| Quigley Jill M. | Chief Operating Officer | 01/14/2021 | 490,570 |
| Countouriotis Athena | Director | 03/24/2020 | 149,750 |
| Ratcliffe Liam | Director | 03/03/2020 | 9,900,000 |
| Ratcliffe Liam | Director | 03/03/2020 | 50,400 |
| ORBIMED ADVISORS LLC | 10% Owner | 02/28/2020 | 6,719,400 |
| Versant Venture Capital VI, L.P. | 10% Owner | 03/03/2020 | 4,050,000 |
| Frazier Life Sciences IX, L.P. | 10% Owner | 03/03/2020 | 9,900,000 |
| Woiwode Thomas | Director | 03/03/2020 | 4,050,000 |
| Heron Patrick J | Director | 03/03/2020 | 9,900,000 |
| Yamada Tadataka | Director | 03/03/2020 | 117,000 |
| Ratcliffe Liam | Director | 03/03/2020 | 50,400 |
| Quigley Jill M. | Chief Operating Officer | 03/03/2020 | 18,000 |
| Quigley Jill M. | Chief Operating Officer | 03/03/2020 | 27,000 |
| Morris Richard Steven | Chief Financial Officer | 03/03/2020 | 7,200 |
| Kapadia Sandip | Director | 03/03/2020 | 90,000 |
| Islam Saqib | Director | 03/03/2020 | 90,000 |
| Goldsmith Bruce A | CEO and President | 03/03/2020 | 19,800 |
| Fotopoulos Alexandros | Chief Technical Officer | 03/03/2020 | 99,000 |
| Countouriotis Athena | Director | 03/03/2020 | 160,200 |
| Cale Edgar B. | GC and Corporate Secretary | 03/03/2020 | 36,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN PASSAGE BIO INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 8,034,000 | 0.21% | -20.65% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 1,223,351 | 0.00191% | 23.02% | Other |
| BLACKROCK INC. | 1,022,563 | 0.00003% | 1.01% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 332,203 | 0.00004% | No change | Other |
CHANGE IN SHARES OUTSTANDING FOR PASSAGE BIO INC
STOCK BUYBACKS FOR PASSAGE BIO INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.17%
1Q
06/30/2023
0.36%
2Q
03/31/2023
0.48%
3Q
12/31/2022
0.55%
4Q
09/30/2022
0.75%
5Q
06/30/2022
0.91%
6Q
03/31/2022
1.11%
7Q
12/31/2021
1.38%
8Q
09/30/2021
1.64%
9Q
06/30/2021
1.85%
10Q
03/31/2021
6.91%
11Q
12/31/2020
20.24%
12Q
09/30/2020
20.61%
13Q
06/30/2020
20.92%
14Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR PASSAGE BIO INC
LOADING...